Apixaban not superior to standard care after TAVR

Post-COVID PTSD? Many find return to ‘normal’ unsettling
17 May 2021
US nurses working in critical care have been severely impacted by the COVID-19 pandemic
17 May 2021

Apixaban not superior to standard care after TAVR

The blood thinner apixaban was not superior to standard of care following transcatheter aortic valve replacement (TAVR), according to findings from a new trial called ATLANTIS presented at the American College of Cardiology’s 70th Annual Scientific Session. Researchers found that while apixaban reduced the formation of blood clots (thrombosis) around the implanted valve with no increased bleeding risk, a subset of patients taking apixaban who did not have an indication for anticoagulation apart from the TAVR procedure showed a tendency toward a higher rate of non-cardiovascular death—a finding researchers said deserves further exploration.

Comments are closed.